Randomized controlled trial of an oral gastrin receptor antagonist for the treatment of postmenopausal osteoporosis
Authors' conclusion
Gastrin receptor antagonist had the expected effects on the gastric markers with an increase in gastrin and a decrease in group I pepsinogens. However, the absence of any change in the bone resorption marker plasma CTX was a bit surprising.
Study context
- Population
- Postmenopausal women; mean age 60 yr, bone mineral density (BMD) T-scores spine −0.96 and total hip −0.0981 completed
- Participants
- 99 women
- Comparison
- Oral gastrin receptor antagonist 100 mg daily for 90 d vs placebo
- Primary endpoint
- Change in the bone turnover markers (BTM) plasma CTX
- Follow-up
- Days 0, 7, 28, 56, and 90
Methodological detailsdouble-blind, placebo-controlled
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Plasma CTX
- No significant change in plasma CTX
Further findings
- Gastrin · as early as 7 d — Gastrin increased in response to gastrin receptor antagonist (GRA)
- 90% · p-value for treatment: .0008
- Group I pepsinogens · as early as 7 d — Group I pepsinogens decreased
- 15% · p-value: .0002
Safety
Tolerability
- Completed the study
- 81/99
- GRA was well tolerated
Original publication
Randomized controlled trial of an oral gastrin receptor antagonist for the treatment of postmenopausal osteoporosis. J Bone Miner Res. Published 8 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →